Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Atovaquone equivalent?Progress of the launch of a generic drug of xiidra eye drops in the united states?What it tecentriq patent cliff?Tablets acetaminophen concorrente del?Rinvoq medication patent?
See the DrugPatentWatch profile for Aubagio
What is Aubagio? Aubagio is a medication branded as teriflunomide, used to treat multiple sclerosis (MS). It is a disease-modifying therapy, designed to slow the progression of MS symptoms and prevent relapses. [1] How does Aubagio work? Aubagio works by inhibiting the activity of an enzyme called dihydroorotate dehydrogenase, which is involved in the production of lymphocytes. By reducing the number of lymphocytes in the body, Aubagio helps to suppress the immune system's attacks on the protective covering of nerves in the central nervous system. [2] Approval and patents Aubagio was approved by the US FDA in 2012 for the treatment of relapsing forms of MS. The medication is sold by Sanofi-Aventis, the manufacturer of Aubagio. According to DrugPatentWatch.com, the patent for Aubagio (teriflunomide) expires in 2030. [3] Side effects and patient concerns Common side effects of Aubagio include nausea, diarrhea, and headache. More serious side effects may include liver damage and neutropenia (a decrease in white blood cells). Patients should seek medical attention if they experience any severe side effects or if their dosage needs to be adjusted. [4] Why are companies challenging the Aubagio patent? Several companies, including Apotex and Roxane, have challenged the Aubagio patent, likely seeking to develop generic versions of the medication before the patent expires in 2030. Sanofi-Aventis may face additional challenges, including increased competition and lower sales, if and when generic versions of Aubagio become available. [5] Timeline - 2012: Aubagio is approved by the US FDA. - 2030: Aubagio patent expires. References: [1] Aubagio. (n.d.). In Multiple Sclerosis News Today. Retrieved from https://multiplesclerosisnewstoday.com/treatment/aubagio/ [2] Teriflunomide. (n.d.). In Wikipedia. Retrieved from https://en.wikipedia.org/wiki/Teriflunomide [3] DrugPatentWatch.com. (n.d.). Teriflunomide patents. Retrieved from https://www.drugpatentwatch.com/patents/teriflunomide [4] Aubagio. (n.d.). In WebMD. Retrieved from https://www.webmd.com/drugs/2/drug-158555/aubagio-oral/details [5] Aubagio patent faces challenges from generics. (2018, October 18). In FiercePharma. Retrieved from https://www.fiercepharma.com/pharma/aubagio-patent-priority-opposition-opens-up-competition
Other Questions About Aubagio :